LNP Collaborations & Partners

Since inception, Arbutus has fostered collaborations and partnerships with leading companies in the RNAi field, including Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals Inc., Merck & Co. Inc., Takeda Pharmaceutical Company, Monsanto, and other undisclosed pharmaceutical and biotechnology companies.

Our Partners


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)

Arbutus has granted a license to Alnylam to use Arbutus' LNP technology to enable RNAi therapeutic products. Arbutus will receive milestone and royalty payments as LNP-enabled products are developed and commercialized. Alnylam currently has three LNP-enabled products in human clinical trials: ALN-TTR02 (patisiran), ALN-VSP, and ALN-PCS02.

Spectrum Pharmaceuticals, Inc.

In 2006, Arbutus licensed three liposomal chemotherapy products to Talon Therapeutics: Marqibo® (a liposomal formulation of the chemotherapy drug vincristine); Alocrest (a liposomal formulation of the chemotherapy drug vinorelbine); and, Brakiva (a liposomal formulation of the chemotherapy drug topotecan). In 2013, Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) acquired Talon Therapeutics. Spectrum has launched Marqibo® through its existing hematology sales force. Arbutus receives royalty payments based on Marqibo®’s commercial sales.

Gritstone Oncology

Gritstone Oncology was granted worldwide access to Arbutus’ portfolio of proprietary and clinically validated lipid nanoparticle (LNP) products and associated intellectual property to deliver Gritstone’s RNA-based neoantigen immunotherapy products. Gritstone will pay Arbutus an upfront payment, payments for achievement of development, regulatory, and commercial milestones, royalties, and will reimburse Arbutus for conducting technology development and providing manufacturing and regulatory support for Gritstone’s product candidates.

 Read more about our Partnered Products here.